These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 15235821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L.
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
    Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ, Gallo JM.
    Clin Cancer Res; 1996 Mar; 2(3):549-52. PubMed ID: 9816202
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.
    Clin Cancer Res; 1998 Oct; 4(10):2321-9. PubMed ID: 9796961
    [Abstract] [Full Text] [Related]

  • 10. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA.
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.
    Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.
    Cancer Chemother Pharmacol; 2007 Jun 16; 60(1):81-9. PubMed ID: 17031646
    [Abstract] [Full Text] [Related]

  • 17. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ.
    Clin Cancer Res; 2004 Dec 15; 10(24):8325-31. PubMed ID: 15623609
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
    Plummer R, Woll P, Fyfe D, Boddy AV, Griffin M, Hewitt P, Carmichael J, Namouni F, Cohen M, Verrill M.
    Clin Cancer Res; 2008 Dec 15; 14(24):8288-94. PubMed ID: 19088046
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I, Sankai Gynecology Study Group (SGSG).
    Gynecol Oncol; 2005 Dec 15; 99(3):591-6. PubMed ID: 16095677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.